Brainomix Collaborated with UK Government-Funded NCIMI for AI-Powered Technology in Lung Cancer
Shots:
- Brainomix & CIMI collaborated along with 3 NHS sites to optimize & validate e-ACT which measures tumor size in lung cancer patients & detects changes in size indicating treatment response & disease progression. The new study builds on an earlier collaboration b/w Brainomix & NCIMI which developed e-Stroke
- The study will involve CAT scans & clinical data from 200 patients with lung cancer on systematic therapy. The research incl. descriptive analysis of tumor dynamics using e-ACT in an NHS cohort
- The collaboration will study the effectiveness of automated assessment via e-ACT over observations of medical specialists. The preliminary results show that e-ACT is good as specialist doctors to measure lung cancer tumors size at a single time point
Ref: Brainomix | Image: Brainomix
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
